MicuRx Says Novel Antibiotic Passes China Phase II Test

MicuRx Pharma, a US-China antibiotics company, announced positive data from a China Phase II clinical trial of MRX-1, the company's lead drug candidate. MRX-1 is an oral oxazolidinone antibiotic aimed at effective treatment of drug-resistant bacteria without the myelosuppression that is typical in other oxazolidinone antibiotics. MicuRx is also conducting a Phase II trial of the antibiotic in the US, whose results are expected in late 2015. More details.... Share this with colleagues: // //